Please Wait.....
Report
Artificial Intelligence In Cancer Diagnostics Market By Component (Software, Services, Hardware) , By Type (Breast cancer, Lung cancer, Prostate cancer, Others) By End user (Hospitals, Diagnostic centers, Others) : Global Opportunity Analysis and Industry Forecast, 2024-2033
Market Report I 2024-07-01 I 280 Pages I Allied Market Research
The artificial intelligence in cancer diagnostics market was valued at $0.2 billion in 2023, and is projected to reach $1.7 billion by 2033, growing at a CAGR of 23.6% from 2024 to 2033.
Artificial intelligence is transforming cancer diagnostics by helping healthcare professionals to detect, analyze, and treat various types of cancer. By leveraging advanced algorithms and machine learning techniques, artificial intelligence enhances the accuracy, speed, and efficiency of diagnostic processes, offering significant benefits to both patients and medical practitioners. Artificial intelligence holds the potential to improve patient outcomes and advance the fight against cancer by enhancing the capabilities of medical professionals and streamlining diagnostic processes.
The growth of the global artificial intelligence in cancer diagnostics market is majorly driven by alarming increase in prevalence of various types of cancer worldwide, which necessitates advanced diagnostic tools to manage and treat the growing number of cases. According to the estimates of the World Health Organization, 20 million cancer cases and 9.7 million deaths were reported in 2022. Moreover, rise in need for early cancer detection and development of personalized treatment plans fosters the need for artificial intelligence to improve patient outcomes. In addition, multiple benefits associated with artificial intelligence in cancer diagnostics significantly contributes toward the market growth. For instance, artificial intelligence helps to alleviate the burden on healthcare systems by supporting radiologists and pathologists as well as artificial intelligence-driven diagnostics can reduce healthcare costs by streamlining processes and minimizing errors. Furthermore, growing awareness and acceptance of artificial intelligence in healthcare among the public and professionals is considerably propelling the market growth. However, high initial investment required for implementation of artificial intelligence, including technology acquisition, training, and maintenance acts as a key deterrent factor of the global market. Integrating artificial intelligence systems with existing healthcare infrastructure and electronic health records is complex and incurs additional cost, thereby restraining the growth of the market. Moreover, dearth of professionals with expertise in both artificial intelligence and healthcare limits the adoption and development of artificial intelligence solutions. On the contrary, incorporating artificial intelligence with telemedicine platforms to provide remote diagnostic services is expected to offer remunerative opportunities for the expansion of the global market during the forecast period. According to the National Cancer Institute, approximately 25,500 telehealth visits were conducted during the pandemic, among which over 11,600 were adult cancer patients who received virtual consultations from clinicians at the Moffitt Cancer Center, a National Cancer Institute-designated Comprehensive Cancer Center located in Florida. Thus, artificial intelligence in telehealth services will enable continuous monitoring of patients with chronic conditions. Furthermore, using artificial intelligence to analyze blood samples offers a non-invasive diagnostic option, which is anticipated to open new avenues for the growth of the market.
The global artificial intelligence in cancer diagnostics market is segmented into component, type, end user, and region. By component, the market is categorized into software, services, and hardware. On the basis of type, it is classified into breast cancer, lung cancer, prostate cancer, and others. Depending on end user, it is fragmented into hospitals, diagnostic centers, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
By component, the software segment dominated the artificial intelligence in cancer diagnostics market in 2023.
On the basis of type, the breast cancer segment is expected to lead the market by 2033.
Depending on end user, the hospital segment exhibited the highest growth in 2023.
Region wise, North America was the major revenue generator in 2023, and is likely to dominate the market during the forecast period.
Competition Analysis
Competitive analysis and profiles of the major players in the global artificial intelligence in cancer diagnostics market include Siemens Healthineers AG, Nanox Imaging LTD, Riverain Technologies, Vuno, Inc., Aidoc, Neural Analytics, Imagen Technologies, Digital Diagnostics, GE Healthcare, and AliveCor Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the competitive market.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- SWOT Analysis
Key Market Segments
By Component
- Software
- Services
- Hardware
By Type
- Breast cancer
- Lung cancer
- Prostate cancer
- Others
By End User
- Hospitals
- Diagnostic centers
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- France
- Germany
- Italy
- Spain
- UK
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- South Africa
- Saudi Arabia
- Rest of LAMEA
- Key Market Players
- Siemens Healthineers AG
- Nanox Imaging LTD
- Riverain Technologies
- Vuno, Inc.
- Aidoc
- Neural Analytics
- Imagen Technologies
- Digital Diagnostics
- GE Healthcare
- AliveCor Inc.
CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: ARTIFICIAL INTERNAL ORGANS MARKET, BY TYPE
4.1. Market Overview
4.1.1 Market Size and Forecast, By Type
4.2. Artificial Heart
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. Artificial Kidney
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
4.4. Artificial Lungs
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.4.2. Market Size and Forecast, By Region
4.4.3. Market Share Analysis, By Country
4.5. Others
4.5.1. Key Market Trends, Growth Factors and Opportunities
4.5.2. Market Size and Forecast, By Region
4.5.3. Market Share Analysis, By Country
CHAPTER 5: ARTIFICIAL INTERNAL ORGANS MARKET, BY END USER
5.1. Market Overview
5.1.1 Market Size and Forecast, By End User
5.2. Hospitals
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Ambulatory Surgical Centers
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
5.4. Others
5.4.1. Key Market Trends, Growth Factors and Opportunities
5.4.2. Market Size and Forecast, By Region
5.4.3. Market Share Analysis, By Country
CHAPTER 6: ARTIFICIAL INTERNAL ORGANS MARKET, BY REGION
6.1. Market Overview
6.1.1 Market Size and Forecast, By Region
6.2. North America
6.2.1. Key Market Trends and Opportunities
6.2.2. Market Size and Forecast, By Type
6.2.3. Market Size and Forecast, By End User
6.2.4. Market Size and Forecast, By Country
6.2.5. U.S. Artificial Internal Organs Market
6.2.5.1. Market Size and Forecast, By Type
6.2.5.2. Market Size and Forecast, By End User
6.2.6. Canada Artificial Internal Organs Market
6.2.6.1. Market Size and Forecast, By Type
6.2.6.2. Market Size and Forecast, By End User
6.2.7. Mexico Artificial Internal Organs Market
6.2.7.1. Market Size and Forecast, By Type
6.2.7.2. Market Size and Forecast, By End User
6.3. Europe
6.3.1. Key Market Trends and Opportunities
6.3.2. Market Size and Forecast, By Type
6.3.3. Market Size and Forecast, By End User
6.3.4. Market Size and Forecast, By Country
6.3.5. France Artificial Internal Organs Market
6.3.5.1. Market Size and Forecast, By Type
6.3.5.2. Market Size and Forecast, By End User
6.3.6. Germany Artificial Internal Organs Market
6.3.6.1. Market Size and Forecast, By Type
6.3.6.2. Market Size and Forecast, By End User
6.3.7. Italy Artificial Internal Organs Market
6.3.7.1. Market Size and Forecast, By Type
6.3.7.2. Market Size and Forecast, By End User
6.3.8. Spain Artificial Internal Organs Market
6.3.8.1. Market Size and Forecast, By Type
6.3.8.2. Market Size and Forecast, By End User
6.3.9. UK Artificial Internal Organs Market
6.3.9.1. Market Size and Forecast, By Type
6.3.9.2. Market Size and Forecast, By End User
6.3.10. Rest of Europe Artificial Internal Organs Market
6.3.10.1. Market Size and Forecast, By Type
6.3.10.2. Market Size and Forecast, By End User
6.4. Asia-Pacific
6.4.1. Key Market Trends and Opportunities
6.4.2. Market Size and Forecast, By Type
6.4.3. Market Size and Forecast, By End User
6.4.4. Market Size and Forecast, By Country
6.4.5. China Artificial Internal Organs Market
6.4.5.1. Market Size and Forecast, By Type
6.4.5.2. Market Size and Forecast, By End User
6.4.6. Japan Artificial Internal Organs Market
6.4.6.1. Market Size and Forecast, By Type
6.4.6.2. Market Size and Forecast, By End User
6.4.7. India Artificial Internal Organs Market
6.4.7.1. Market Size and Forecast, By Type
6.4.7.2. Market Size and Forecast, By End User
6.4.8. South Korea Artificial Internal Organs Market
6.4.8.1. Market Size and Forecast, By Type
6.4.8.2. Market Size and Forecast, By End User
6.4.9. Australia Artificial Internal Organs Market
6.4.9.1. Market Size and Forecast, By Type
6.4.9.2. Market Size and Forecast, By End User
6.4.10. Rest of Asia-Pacific Artificial Internal Organs Market
6.4.10.1. Market Size and Forecast, By Type
6.4.10.2. Market Size and Forecast, By End User
6.5. LAMEA
6.5.1. Key Market Trends and Opportunities
6.5.2. Market Size and Forecast, By Type
6.5.3. Market Size and Forecast, By End User
6.5.4. Market Size and Forecast, By Country
6.5.5. Brazil Artificial Internal Organs Market
6.5.5.1. Market Size and Forecast, By Type
6.5.5.2. Market Size and Forecast, By End User
6.5.6. South Africa Artificial Internal Organs Market
6.5.6.1. Market Size and Forecast, By Type
6.5.6.2. Market Size and Forecast, By End User
6.5.7. Saudi Arabia Artificial Internal Organs Market
6.5.7.1. Market Size and Forecast, By Type
6.5.7.2. Market Size and Forecast, By End User
6.5.8. Rest of LAMEA Artificial Internal Organs Market
6.5.8.1. Market Size and Forecast, By Type
6.5.8.2. Market Size and Forecast, By End User
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top Winning Strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top Player Positioning, 2023
CHAPTER 8: COMPANY PROFILES
8.1. SynCardia Systems LLC
8.1.1. Company Overview
8.1.2. Key Executives
8.1.3. Company Snapshot
8.1.4. Operating Business Segments
8.1.5. Product Portfolio
8.1.6. Business Performance
8.1.7. Key Strategic Moves and Developments
8.2. Abbott Laboratories
8.2.1. Company Overview
8.2.2. Key Executives
8.2.3. Company Snapshot
8.2.4. Operating Business Segments
8.2.5. Product Portfolio
8.2.6. Business Performance
8.2.7. Key Strategic Moves and Developments
8.3. Cochlear Limited
8.3.1. Company Overview
8.3.2. Key Executives
8.3.3. Company Snapshot
8.3.4. Operating Business Segments
8.3.5. Product Portfolio
8.3.6. Business Performance
8.3.7. Key Strategic Moves and Developments
8.4. Boston Scientific Corporation
8.4.1. Company Overview
8.4.2. Key Executives
8.4.3. Company Snapshot
8.4.4. Operating Business Segments
8.4.5. Product Portfolio
8.4.6. Business Performance
8.4.7. Key Strategic Moves and Developments
8.5. Johnson And Johnson
8.5.1. Company Overview
8.5.2. Key Executives
8.5.3. Company Snapshot
8.5.4. Operating Business Segments
8.5.5. Product Portfolio
8.5.6. Business Performance
8.5.7. Key Strategic Moves and Developments
8.6. Edwards Lifesciences Corporation
8.6.1. Company Overview
8.6.2. Key Executives
8.6.3. Company Snapshot
8.6.4. Operating Business Segments
8.6.5. Product Portfolio
8.6.6. Business Performance
8.6.7. Key Strategic Moves and Developments
8.7. Zimmer Biomet Holding Inc.
8.7.1. Company Overview
8.7.2. Key Executives
8.7.3. Company Snapshot
8.7.4. Operating Business Segments
8.7.5. Product Portfolio
8.7.6. Business Performance
8.7.7. Key Strategic Moves and Developments
8.8. Berlin Heart GmbH
8.8.1. Company Overview
8.8.2. Key Executives
8.8.3. Company Snapshot
8.8.4. Operating Business Segments
8.8.5. Product Portfolio
8.8.6. Business Performance
8.8.7. Key Strategic Moves and Developments
8.9. Jarvik Heart, Inc.
8.9.1. Company Overview
8.9.2. Key Executives
8.9.3. Company Snapshot
8.9.4. Operating Business Segments
8.9.5. Product Portfolio
8.9.6. Business Performance
8.9.7. Key Strategic Moves and Developments
8.10. Medtronic Plc.
8.10.1. Company Overview
8.10.2. Key Executives
8.10.3. Company Snapshot
8.10.4. Operating Business Segments
8.10.5. Product Portfolio
8.10.6. Business Performance
8.10.7. Key Strategic Moves and Developments
TABLE 1. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 2. ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET FOR SOFTWARE, BY REGION, 2024 - 2033 ($BILLION)
TABLE 3. ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET FOR SERVICES, BY REGION, 2024 - 2033 ($BILLION)
TABLE 4. ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET FOR HARDWARE, BY REGION, 2024 - 2033 ($BILLION)
TABLE 5. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 6. ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET FOR BREAST CANCER, BY REGION, 2024 - 2033 ($BILLION)
TABLE 7. ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET FOR LUNG CANCER, BY REGION, 2024 - 2033 ($BILLION)
TABLE 8. ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY REGION, 2024 - 2033 ($BILLION)
TABLE 9. ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 11. ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 12. ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 13. ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 14. ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY REGION, 2024 - 2033 ($BILLION)
TABLE 15. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 16. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 17. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 18. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 19. U.S. ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 20. U.S. ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 21. U.S. ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 22. CANADA ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 23. CANADA ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 24. CANADA ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 25. MEXICO ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 26. MEXICO ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 27. MEXICO ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 28. EUROPE ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 29. EUROPE ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 30. EUROPE ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 31. EUROPE ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 32. FRANCE ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 33. FRANCE ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 34. FRANCE ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 35. GERMANY ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 36. GERMANY ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 37. GERMANY ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 38. ITALY ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 39. ITALY ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 40. ITALY ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 41. SPAIN ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 42. SPAIN ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 43. SPAIN ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 44. UK ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 45. UK ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 46. UK ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 47. REST OF EUROPE ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 48. REST OF EUROPE ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 49. REST OF EUROPE ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 50. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 51. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 52. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 53. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 54. CHINA ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 55. CHINA ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 56. CHINA ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 57. JAPAN ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 58. JAPAN ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 59. JAPAN ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 60. INDIA ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 61. INDIA ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 62. INDIA ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 63. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 64. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 65. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 66. AUSTRALIA ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 67. AUSTRALIA ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 68. AUSTRALIA ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 69. REST OF ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 70. REST OF ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 71. REST OF ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 72. LAMEA ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 73. LAMEA ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 74. LAMEA ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 75. LAMEA ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 76. BRAZIL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 77. BRAZIL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 78. BRAZIL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 79. SOUTH AFRICA ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 80. SOUTH AFRICA ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 81. SOUTH AFRICA ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 82. SAUDI ARABIA ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 83. SAUDI ARABIA ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 84. SAUDI ARABIA ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 85. REST OF LAMEA ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 86. REST OF LAMEA ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 87. REST OF LAMEA ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 88. SIEMENS HEALTHINEERS AG: KEY EXECUTIVES
TABLE 89. SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT
TABLE 90. SIEMENS HEALTHINEERS AG: OPERATING SEGMENTS
TABLE 91. SIEMENS HEALTHINEERS AG: PRODUCT PORTFOLIO
TABLE 92. SIEMENS HEALTHINEERS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 93. NANOX IMAGING LTD: KEY EXECUTIVES
TABLE 94. NANOX IMAGING LTD: COMPANY SNAPSHOT
TABLE 95. NANOX IMAGING LTD: OPERATING SEGMENTS
TABLE 96. NANOX IMAGING LTD: PRODUCT PORTFOLIO
TABLE 97. NANOX IMAGING LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 98. RIVERAIN TECHNOLOGIES: KEY EXECUTIVES
TABLE 99. RIVERAIN TECHNOLOGIES: COMPANY SNAPSHOT
TABLE 100. RIVERAIN TECHNOLOGIES: OPERATING SEGMENTS
TABLE 101. RIVERAIN TECHNOLOGIES: PRODUCT PORTFOLIO
TABLE 102. RIVERAIN TECHNOLOGIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 103. VUNO, INC.: KEY EXECUTIVES
TABLE 104. VUNO, INC.: COMPANY SNAPSHOT
TABLE 105. VUNO, INC.: OPERATING SEGMENTS
TABLE 106. VUNO, INC.: PRODUCT PORTFOLIO
TABLE 107. VUNO, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 108. AIDOC: KEY EXECUTIVES
TABLE 109. AIDOC: COMPANY SNAPSHOT
TABLE 110. AIDOC: OPERATING SEGMENTS
TABLE 111. AIDOC: PRODUCT PORTFOLIO
TABLE 112. AIDOC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 113. NEURAL ANALYTICS: KEY EXECUTIVES
TABLE 114. NEURAL ANALYTICS: COMPANY SNAPSHOT
TABLE 115. NEURAL ANALYTICS: OPERATING SEGMENTS
TABLE 116. NEURAL ANALYTICS: PRODUCT PORTFOLIO
TABLE 117. NEURAL ANALYTICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 118. IMAGEN TECHNOLOGIES: KEY EXECUTIVES
TABLE 119. IMAGEN TECHNOLOGIES: COMPANY SNAPSHOT
TABLE 120. IMAGEN TECHNOLOGIES: OPERATING SEGMENTS
TABLE 121. IMAGEN TECHNOLOGIES: PRODUCT PORTFOLIO
TABLE 122. IMAGEN TECHNOLOGIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 123. DIGITAL DIAGNOSTICS: KEY EXECUTIVES
TABLE 124. DIGITAL DIAGNOSTICS: COMPANY SNAPSHOT
TABLE 125. DIGITAL DIAGNOSTICS: OPERATING SEGMENTS
TABLE 126. DIGITAL DIAGNOSTICS: PRODUCT PORTFOLIO
TABLE 127. DIGITAL DIAGNOSTICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 128. GE HEALTHCARE: KEY EXECUTIVES
TABLE 129. GE HEALTHCARE: COMPANY SNAPSHOT
TABLE 130. GE HEALTHCARE: OPERATING SEGMENTS
TABLE 131. GE HEALTHCARE: PRODUCT PORTFOLIO
TABLE 132. GE HEALTHCARE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 133. ALIVECOR INC.: KEY EXECUTIVES
TABLE 134. ALIVECOR INC.: COMPANY SNAPSHOT
TABLE 135. ALIVECOR INC.: OPERATING SEGMENTS
TABLE 136. ALIVECOR INC.: PRODUCT PORTFOLIO
TABLE 137. ALIVECOR INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
FIGURE 1. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, 2024 - 2033
FIGURE 2. SEGMENTATION OF ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET, 2024 - 2033
FIGURE 3. TOP INVESTMENT POCKET IN ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET
FIGURE 4. MODERATE BARGAINING POWER OF BUYERS
FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 6. MODERATE THREAT OF NEW ENTRANTS
FIGURE 7. LOW THREAT OF SUBSTITUTION
FIGURE 8. HIGH COMPETITIVE RIVALRY
FIGURE 9. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET
FIGURE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SEGMENTATION, BY COMPONENT
FIGURE 11. ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET FOR SOFTWARE, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 12. ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET FOR SERVICES, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 13. ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET FOR HARDWARE, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 14. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SEGMENTATION, BY TYPE
FIGURE 15. ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 16. ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 17. ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 18. ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 19. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SEGMENTATION, BY END USER
FIGURE 20. ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 21. ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET FOR DIAGNOSTIC CENTERS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 22. ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 23. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*
FIGURE 24. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*
FIGURE 25. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*
FIGURE 26. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 27. COMPETITIVE DASHBOARD
FIGURE 28. COMPETITIVE HEATMAP: ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET
FIGURE 29. TOP PLAYER POSITIONING, 2023
FIGURE 30. SIEMENS HEALTHINEERS AG: NET SALES, 2021-2023 ($BILLION)
FIGURE 31. SIEMENS HEALTHINEERS AG: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 32. SIEMENS HEALTHINEERS AG: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 33. NANOX IMAGING LTD: NET SALES, 2021-2023 ($BILLION)
FIGURE 34. NANOX IMAGING LTD: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 35. NANOX IMAGING LTD: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 36. RIVERAIN TECHNOLOGIES: NET SALES, 2021-2023 ($BILLION)
FIGURE 37. RIVERAIN TECHNOLOGIES: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 38. RIVERAIN TECHNOLOGIES: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 39. VUNO, INC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 40. VUNO, INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 41. VUNO, INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 42. AIDOC: NET SALES, 2021-2023 ($BILLION)
FIGURE 43. AIDOC: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 44. AIDOC: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 45. NEURAL ANALYTICS: NET SALES, 2021-2023 ($BILLION)
FIGURE 46. NEURAL ANALYTICS: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 47. NEURAL ANALYTICS: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 48. IMAGEN TECHNOLOGIES: NET SALES, 2021-2023 ($BILLION)
FIGURE 49. IMAGEN TECHNOLOGIES: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 50. IMAGEN TECHNOLOGIES: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 51. DIGITAL DIAGNOSTICS: NET SALES, 2021-2023 ($BILLION)
FIGURE 52. DIGITAL DIAGNOSTICS: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 53. DIGITAL DIAGNOSTICS: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 54. GE HEALTHCARE: NET SALES, 2021-2023 ($BILLION)
FIGURE 55. GE HEALTHCARE: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 56. GE HEALTHCARE: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 57. ALIVECOR INC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 58. ALIVECOR INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 59. ALIVECOR INC.: REVENUE SHARE, BY REGION, 2023 (%)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security